SCHEMBL485985

SCHEMBL485985

CC1(C)CC(NC(=O)c2ccccc2Cl)c2cc(C(=O)O)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYGL P06737 2/20 0.46
ALDH1A1 P00352 1/20 0.44
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SPTLC2 O15270 4/20 0.42
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
TAS1R2 Q8TE23 1/20 0.42
F10 P00742 1/20 0.41
CYP1A2 P05177 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40
RXRA P19793 2/20 0.40
GRM2 Q14416 1/20 0.40
GRM3 Q14832 1/20 0.40
RARB P10826 1/20 0.40
RARG P13631 1/20 0.40
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15235436 1.00 PYGL (0.46) PYGLALDH1A1NPC1RAB9ASPTLC2
SCHEMBL485219 0.89 WDR5 (0.47) ALDH1A1NPC1RAB9ASPTLC2TAS1R3
SCHEMBL485983 0.83 SMN1; SMN2 (0.41) PYGLALDH1A1NPC1RAB9ARXRA
SCHEMBL485126 0.78 ALDH1A1 (0.61) PYGLALDH1A1SPTLC2TAS1R3TAS1R1
SCHEMBL484760 0.78 ALDH1A1 (0.61) PYGLALDH1A1SPTLC2TAS1R3TAS1R1
SCHEMBL785249 0.78 ALDH1A1 (0.61) PYGLALDH1A1SPTLC2TAS1R3TAS1R1
SCHEMBL2815476 0.78 PYGL (0.46) PYGLALDH1A1NPC1RAB9AF10
SCHEMBL484805 0.77 CYP2C9 (0.48) ALDH1A1CYP1A2HPGDCYP2C19
SCHEMBL2817561 0.76 ALDH1A1 (0.72) ALDH1A1TAS1R3TAS1R1TAS1R2KMT2A
SCHEMBL788838 0.76 ALDH1A1 (0.72) ALDH1A1TAS1R3TAS1R1TAS1R2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130231327-A1 Substituted Spiro-Amide Compounds GRUENENTHAL GMBH (DE) 2013-09-05 US disclosed
US-20130231327-A1 Substituted Spiro-Amide Compounds GRUENENTHAL GMBH (DE) 2013-09-05 US disclosed
US-20130231327-A1 Substituted Spiro-Amide Compounds GRUENENTHAL GMBH (DE) 2013-09-05 US disclosed
US-8455475-B2 Substituted spiro-amide compounds GRUENENTHAL GMBH (DE) 2013-06-04 US disclosed
US-8455475-B2 Substituted spiro-amide compounds GRUENENTHAL GMBH (DE) 2013-06-04 US disclosed
US-8455475-B2 Substituted spiro-amide compounds GRUENENTHAL GMBH (DE) 2013-06-04 US disclosed
EP-2411381-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-02-01 EP disclosed
US-20100249095-A1 Substituted Spiro-amide Compounds GRUENENTHAL GMBH (DE) 2010-09-30 US disclosed
US-20100249095-A1 Substituted Spiro-amide Compounds GRUENENTHAL GMBH (DE) 2010-09-30 US disclosed
US-20100249095-A1 Substituted Spiro-amide Compounds GRUENENTHAL GMBH (DE) 2010-09-30 US disclosed
WO-2010108651-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2010-09-30 WO disclosed
WO-2010108651-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231327-A1 Substituted Spiro-Amide Compounds BDKRB1, BDKRB2, REN PYGL 4133/4885ALDH1A1 2086/4885NPC1 1121/4885
US-20100249095-A1 Substituted Spiro-amide Compounds BDKRB1, BDKRB2, REN PYGL 4133/4885ALDH1A1 2086/4885NPC1 1121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.